These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34251311)

  • 41. Pulmonary complications of polymyositis and dermatomyositis.
    Fathi M; Lundberg IE; Tornling G
    Semin Respir Crit Care Med; 2007 Aug; 28(4):451-8. PubMed ID: 17764062
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A bibliometric analysis of the research status and trends in studies on polymyositis and dermatomyositis with interstitial lung disease from 2000 to 2022 using Web of Science.
    Ma XN; Feng W; Chen SL; Zhong XQ; Zheng XX; Lin CS; Xu Q
    Immun Inflamm Dis; 2024 Feb; 12(2):e1190. PubMed ID: 38376948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis.
    Sato S; Uejima Y; Nanbu M; Suganuma E; Takano T; Tanaka R; Kabuki T; Oguma E; Oh-Ishi T; Kawano Y
    Mod Rheumatol; 2017 Jul; 27(4):652-656. PubMed ID: 27588444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
    Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
    Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interstitial Lung Disease in Polymyositis and Dermatomyositis.
    Long K; Danoff SK
    Clin Chest Med; 2019 Sep; 40(3):561-572. PubMed ID: 31376891
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
    Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
    Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
    Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study.
    Nakazawa M; Kaneko Y; Takeuchi T
    Clin Rheumatol; 2018 Mar; 37(3):765-771. PubMed ID: 28975463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinical characteristics of two anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody-positive interstitial lung disease patients with polymyositis/dermatomyositis.
    Kunimasa K; Arita M; Nakazawa T; Tanaka M; Tsubouchi K; Konishi S; Fukuda Y; Saigusa M; Nakagawa H; Ubukata S; Korogi Y; Fujii T; Mimori T; Ishida T
    Intern Med; 2012; 51(24):3405-10. PubMed ID: 23257529
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
    Lega JC; Cottin V; Fabien N; Thivolet-Béjui F; Cordier JF
    J Rheumatol; 2010 May; 37(5):1000-9. PubMed ID: 20231208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The clinical phenotype of patients positive for antibodies to myositis and myositis-related disorders.
    Gofrit SG; Yonath H; Lidar M; Shoenfeld Y; Kivity S
    Clin Rheumatol; 2018 May; 37(5):1257-1263. PubMed ID: 29453582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Classification of idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific antibodies].
    Zheng S; Chen S; Wu L; Zhao D; Chen F; Zhu J; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Jul; 40(7):1029-1035. PubMed ID: 32895158
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease.
    Cobo-Ibáñez T; López-Longo FJ; Joven B; Carreira PE; Muñoz-Fernández S; Maldonado-Romero V; Larena-Grijalba C; Cubas IL; Muriel ET; Mateos CB; de la Peña Lefebvre PG; Gomez-Gomez A; Nogal LB; Pérez A; Almodovar R; Lojo L; Ruiz-Gutiérrez L; López-Robledillo JC; García de Yébenes MJ; Nuño-Nuño L
    Clin Rheumatol; 2019 Mar; 38(3):803-815. PubMed ID: 30392161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome.
    Lega JC; Fabien N; Reynaud Q; Durieu I; Durupt S; Dutertre M; Cordier JF; Cottin V
    Autoimmun Rev; 2014 Sep; 13(9):883-91. PubMed ID: 24704867
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease.
    Nishina N; Sato S; Masui K; Gono T; Kuwana M
    RMD Open; 2020 Jun; 6(2):. PubMed ID: 32506053
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis.
    Vojinovic T; Cavazzana I; Ceruti P; Fredi M; Modina D; Berlendis M; Franceschini F
    Clin Rev Allergy Immunol; 2021 Feb; 60(1):87-94. PubMed ID: 33141387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy.
    Bai Z; Shen G; Dong L
    Int J Rheum Dis; 2021 Jun; 24(6):815-827. PubMed ID: 34028988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
    Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
    Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.